Bionano Genomics Stock Filter Stocks by Fundamentals
| BNGO Stock | USD 0.76 0.03 3.66% |
Bionano Genomics fundamentals help investors to digest information that contributes to Bionano Genomics' financial success or failures. It also enables traders to predict the movement of Bionano Stock. The fundamental analysis module provides a way to measure Bionano Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionano Genomics stock.
Bionano | Shares Owned by Institutions |
Bionano Genomics Institutional Holders
Institutional Holdings refers to the ownership stake in Bionano Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bionano Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bionano Genomics' value.| Shares | Gsa Capital Partners Llp | 2023-12-31 | 86.9 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 82.3 K | Archford Capital Strategies, Llc | 2023-12-31 | 69.6 K | Jane Street Group, Llc | 2023-12-31 | 68.6 K | Engineers Gate Manager Lp | 2023-12-31 | 60.2 K | Fmr Inc | 2023-12-31 | 53.6 K | Two Sigma Securities, Llc | 2023-12-31 | 49.4 K | Susquehanna International Group, Llp | 2023-12-31 | 42 K | Headlands Technologies Llc | 2023-12-31 | 38 K | Vanguard Group Inc | 2023-12-31 | 1.9 M | Gmt Capital Corp | 2023-12-31 | 530.3 K |
Bionano Fundamentals
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 56.09 M | ||||
| Shares Outstanding | 61.23 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 11.96 % | ||||
| Number Of Shares Shorted | 5.27 M | ||||
| Price To Earning | (1.80) X | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 1.66 X | ||||
| Revenue | 36.12 M | ||||
| Gross Profit | 5.95 M | ||||
| EBITDA | (125.72 M) | ||||
| Net Income | (232.49 M) | ||||
| Cash And Equivalents | 187.34 M | ||||
| Cash Per Share | 0.65 X | ||||
| Total Debt | 87.95 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.75 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (129.7 M) | ||||
| Short Ratio | 3.69 X | ||||
| Earnings Per Share | (6.81) X | ||||
| Target Price | 6.67 | ||||
| Number Of Employees | 344 | ||||
| Beta | 2.37 | ||||
| Market Capitalization | 48.64 M | ||||
| Total Asset | 214.4 M | ||||
| Retained Earnings | (581.21 M) | ||||
| Working Capital | 40.09 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 8.72 M | ||||
| Net Asset | 214.4 M |
About Bionano Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionano Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionano Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionano Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bionano Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bionano Genomics' short interest history, or implied volatility extrapolated from Bionano Genomics options trading.
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
| 0.7 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.83 | DRMA | Dermata Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Bionano Stock
| 0.78 | YS | YS Biopharma | PairCorr |
| 0.71 | FUSN | Fusion PharmaceuticalsInc Financial Report 9th of May 2024 | PairCorr |
| 0.7 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.67 | HCM | HUTCHMED DRC | PairCorr |
| 0.65 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bionano Genomics Piotroski F Score and Bionano Genomics Altman Z Score analysis. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Bionano Stock analysis
When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.81) | Revenue Per Share 1.058 | Quarterly Revenue Growth 0.305 | Return On Assets (0.33) | Return On Equity (1.35) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.